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1Chapter
Lessons Learned and Recent 
Advances in Dengue Research
Juan Samuel Sulca Herencia
Abstract
Dengue is the most important arbovirus, many research have contributed to 
the diagnosis, management, prevention and control of this disease, which will be 
described in this chapter, for example: the importance of serotypes and genotypes 
for the development of the disease, the relationship of the viral load between symp-
tomatic and asymptomatic people, the influence of antibodies on the development 
of the disease, co-infections with microorganisms and chronic diseases, possible 
reservoirs, the diagnostic assays, cross-reactions in the diagnosis, the influence of 
climate change on the disease and the vector, mechanisms of transmission of the 
disease, new drugs and plant extracts with antiviral activity, the dengue vaccine, 
the results of immunizations, etc. This information gives a concrete idea of the 
advances and challenges against this disease.
Keywords: dengue, dengue virus, arbovirus, flavivirus, Flaviviridae
1. Introduction
Dengue is a single systematic and dynamic disease that includes severe and 
non-severe clinical manifestations [1]. It is caused by any of the four dengue virus 
serotypes and it is transmitted by Aedes mosquito bites, being the main vector Aedes 
aegypti [1]. Dengue can be maintained in an urban cycle which involves humans 
and it is a serious health problem worldwide [1]. For the past decades, this disease 
has been spread alarmingly due to different factors like climate change, migration 
of people, tourism, lack of access to basic services, etc. [1, 2]. Not only does it affect 
a large portion of the world’s population but also it offers lessons in health sector, 
research and epidemiology which must be skilled to help in better understanding of 
the cycle of this disease, set out control strategies and lead the way to future investi-
gations. Thus, in this chapter we are going to discuss some of the main lessons learnt 
throughout work experiences with this disease and we will learn new strategies 
designed for studies, assessment and control.
2.  Dissemination of the disease in urban areas and transmission 
mechanisms
Dengue is the most important and common arbovirus in more than 100 
countries [1]. This disease is caused by one of the four serotypes of dengue virus 
(DENV), more than one dengue serotype can be found in many geographical areas 
(phenomenon called hyperendemicity) [1]. Outbreaks of this disease have been 
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reported in America, Africa, Mid-west, Asia and the Pacific islands [2]. Nearly 3 
billion people (40% of world population) are at risk in areas where dengue occurs, 
and about 70% of the population at risk are in South East Asia and Western Pacific 
region [2]. About 400 million people are infected with dengue annually, of which 
100 million people are sick and 22,000 die of severe dengue [3]. A virus, a vec-
tor and a sensitive population must be in the same geographic area for a dengue 
onset outbreak [1]. Travelers contribute to dengue dissemination to non-endemic 
areas but they may also serve as sentinels for warning dissemination. Some studies 
indicate that dengue represents about 2% of the diseases from travelers returning to 
from endemic areas [4]. Based on GeoSentinel, a data-collection network between 
1997 and 2006, dengue was imported from South-east Asia (51%), South Central 
Asia (17%), Latin America (15%), the Caribbean (9%), parts of Africa (5%) and 
Oceania (2%) [4]. The number of febrile travelers returning from the tropics and 
sub-tropical areas being diagnosed with dengue has increased from 2% in the 1990s 
to 16% by 2005 [4]. A study of paedriatic travelers in 19 countries reported dengue 
and typhoid fever as the most often febrile diseases in children returning from 
tropical regions and sub-Saharan Africa [4]. Aedes aegypti vector can be dissemi-
nated relatively easy in urban areas because of its strong anthropophilic habits, its 
biological features like egg resistance to desiccation, its permanence within and 
not away from the urban centers, and the search for water with low load of organic 
matter for its oviposition making its arrival in rural areas, where the temperature 
enables its replication, relatively simple; transform cemeteries, tire repair shop, bus 
terminals, etc. in critical points of infestation where the vector surveillance must 
be carried out [5]. The virus can reach new areas where cases of symptomatic and 
asymptomatic persons or cases of people’s incubation period of the disease have 
not been reported. Around three-quarters of dengue infections presented each year 
are clinically inapparent, the asymptomatic ones were considered dead-end hosts 
because they do not produce high enough viremia to infect mosquitoes [6]. Some 
studies provide evidence that despite a low level of viremia, dengue asymptomatic 
persons were capable of transmitting the disease to mosquitoes and potentially 
enabling a high virus transmission. Since it has no symptoms, they could continue 
in their day-to-day work and be exposed to mosquito bites [6]. The virus can also be 
spread through infected mosquitoes so that once the mosquito is infected and the 
extrinsic incubation period is passed, it can be a lifelong carrier of the virus which 
is about 2 weeks or a month. The interruption of dengue transmission was possible 
in the 60s and at the beginning of the 70s as a result of an Aedes aegypti eradication. 
The lack of surveillance and vector control followed outbreaks in the Caribbean, 
Central America and South America [1]. From this experience, it is considered that 
vector control and epidemiological services detecting and studying dengue cases 
have to work together and maintain a constant vigilance [1]. The monitoring service 
should be capable of making the difference between a seasonal and/or temporary 
increase and increases in the number of cases resulting from a dengue outbreak 
so that tools of epidemiology as the endemic channel are highly important. If the 
number of cases reported is higher in two standard deviations above the endemic 
channel in monthly or weekly notifications, a warning of dengue is produced [1, 7]. 
However, the lack of notifications continues to be one of the most significant prob-
lems in order to prevent and control this disease in many countries as well as in the 
western Pacific region [1]. The Geographic Information Systems (GIS) allows the 
analysis of this information on the geographical reference basis in space and time. 
This type of systems is important for vector-borne disease surveillance and vector 
control strategy planning [8]. DENV can be transmitted to humans through the bite 
of female mosquitoes of the Aedes aegypti. Other dengue transmission mechanism 
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is the perinatal transmission and it occurs when a mother is infected near the 
childbirth so that the infection can be transmitted through microtransfusion when 
a placental abruption occurs or during delivery when the mother’s blood gets in 
contact with the newborn’s mucosal. Dengue in pregnancy is related to premature 
delivery, fetal distress in labour, intrauterine death and miscarriages. DENV can 
also be transmitted through breast milk or exposure to blood, organs or infected tis-
sues like bone marrow [9]. In a study carried out at the Brazilian blood center from 
February to June in 2012, donors tested positive for DENV-3 and DENV-4 were 
found and 42 units of PCR tested positive were transfused in 35 recipients. Of these 
findings, 16 units testing positive were transfused in 16 sensitive recipients in which 
5 possible cases transmitted by transfusion (TT) were found, 1 case was considered 
as a possible TT, and 10 of them were not transmitted. However, no significant dif-
ferences were found between symptoms and mortality in cases and controls [10].
3. Dengue virus serotypes and genotypes and its relation to clinical cases
The evolution of molecular biology and phylogenetic analysis has enabled 
molecular epidemiology studies binding DENV-phylogenetic analysis which was 
found in different geographic areas within a certain period of time and clinical 
and epidemiological data in order to establish a relation to genotypes and lineages 
which are found with other circulating strains as well as to identify the origin and 
the transmission route, the severity of the disease, etc. There are four related DENV 
serotypes but antigenically different DENV-1, DENV-2, DENV-3, DENV-4 and each 
of them generates an immune response to the infection. The nucleotide sequences 
show 63–68% homology within the DENV group in comparison with 44% between 
DENV and Yellow Fever virus (YFV), and 51% between DENV and West Nile virus 
(WNV), and it shares a minor homology at 80% at a level of amino acids [11]. 
Previous studies based on partial (prM/E), partial or complete E gene; or complete 
genomic sequences recognized distinct DENV genotypes [12] (Table 1).
The genotypes may present different lineages or clades. The genetic changes in 
the virus are caused by mutations or the introduction of a new variant from other 
region, thus genotyping of strain virus is used to identify the epidemic outbreak 
source and spread [12]. Some dengue genotypes are related to a higher virulence. 
DENV-2 and DENV-3 Asian genotypes are associated with severe infections [1]. In 
South East Asia, dengue hemorrhagic fever (DHF) and/or dengue shock syndrome 
(DSS) outbreaks are caused by DENV-2 southeast Asian genotype strain, mean-
while epidemics caused by DENV-2 in Latin America presents solely dengue fever 
(DF) in most cases. The DENV-2 genotypes circulating in the United States seem 
to be less virulent. Because of the introduction of the South East Asian genotype 
virulent, the number of cases of DHF and DSS in America has increased [1, 11].
It is thought that an infection with DENV serotype provides lifelong immunity 
against the same serotype infection and short-term protection against infection 
by a 2 or 3 month-heterologous serotype [1, 11]. Some studies contradict the 
hypothesis that has been accepted until now. In 2010–2011 a study in DENV-2 
American/Asian genotype outbreak was conducted in Iquitos, Peru. It was carried 
out 15 years after the first DENV-2 American genotype in that region. The results 
on the study showed that protection against homologous DENV-2 may be incom-
plete [13]. In another study carried out in Peru, it was found that the antibodies 
of a primary infection against DENV-1 neutralized more efficiently in American 
DENV-2 than in Asian DENV-2. It is believed that this cross-protective immunity is 
not so strong to inhibit viremia but it may contribute to reduce DENV-2 infection 
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symptomatology [14]. In 2013 evidences of a new dengue serotype appearance 
(DENV-5) that was identified in serum samples collected in 2007 during an 
epidemic in Malaysia were documented. Initially, it was thought that DENV-4 
cases will circulate between primates and Aedes nivalis mosquitoes in the woods at 
South East Asia. However, it was shown that this virus was genetically different to 
DENV-4 from the rainforest and it had certain similarities to DENV-2 when the 
virus was isolated and after sequencing the whole genome, rhesus macaques were 
infected with four dengue serotypes. Once recovered from the infection, the mon-
keys were inoculated with DENV-5 which produced different antibodies. Moreover, 
it was observed that the infection with DENV-5 virus titer was four times higher 
than other serotypes. On the basis of this, it was concluded that DENV-5 will be 
a new serotype. It is thought that this new serotype may mainly circulate in non-
human primates (NHP). This new serotype has only been found in the Woods of 
Sarawak [15]. However, there is a possibility that this new serotype may spread 
to human population becoming a public health concern. Thus, phylogenetics and 
epidemiological surveillance studies are required.
Dengue 
serotype
Genotype Geographical distribution
DENV-1 I Southeast Asia, China, The Middle East
II Thailand
III (Sylvatic) Malaysia
IV Countries of the Pacific Rim, the Western Pacific, islands and 
Australia
V The Americas, West Africa and Asia
DENV-2 Asian I Thailand, Malaysia, Cambodia, Myanmar, Vietnam and Australia
Asian II China, Indonesia, The Philippines, Taiwan, Sri Lanka, India, 
Honduras and Mexico
Southeast Asian/
American
Southeast Asia, Central and South America and the Caribbean
Cosmopolitan East and West Africa, the Middle East, the Indian subcontinent, 
Indian and Pacific Ocean Islands, Australia, Mexico
American Central and South America, the Caribbean and the Indian 
subcontinent and the Pacific Islands
Sylvatic West Africa and Southeast Asia
DENV-3 I Southeast Asia, the Philippines and the South Pacific islands
II Continental Southeast Asia
III Asia, East Africa, the Americas
IV Puerto Rico and Tahiti
DENV-4 I The Philippines, Thailand, Vietnam, Myanmar, Malaysia, Sri 
Lanka, India
II Southeast Asia (Indonesia, Malaysia, Singapore), China, islands 
of the Western Pacific Ocean, Australia, the Caribbean and the 
Americas
III Thailand
IV Malaysia
Table 1. 
Dengue virus serotypes and genotypes and its geographical distribution.
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4.  Factors that increase dengue severity, cases and co-infection 
classification
Most of dengue infections are subclinical or asymptomatic. Dengue epidemics 
were presented in Cuba in 1981 and 1987, and most cases of dengue shock and hem-
orrhagic dengue were mainly found in white population than in afro-descendants 
[16]. In studies carried out in Brazil and El Salvador, it was found that the African 
descent was a protective factor in dengue hemorrhagic manifestations [16]. In a 
dengue outbreak in Santiago de Cuba in 1997, it was found that hemorrhagic dengue 
cases were reported more frequently in patients aged between 15 and 39 years old. 
Additionally, they found a history of asthma in a 16.5% of the cases [17]. The WHO 
estimates that, by 2030, the diabetes mellitus will have been the 7th leading cause 
of death. A study carried out for evaluating the influence of diabetes mellitus and 
its relation to clinical manifestations of dengue, indicated higher risks of dengue 
symptoms potentially fatal within patients developing diabetes mellitus [18]. Other 
risk factors such as sickle-cell disease, uremia, allergies, hypertension, chronic 
renal failure may enable disease severity [1]. Regarding age, the lower compensa-
tion capacity of capillary plasma extravasation in children increases dengue shock 
risk. It has been observed that serious dengue cases were continuously presented 
in primary infections from breastfeeding babies whose mothers were developing 
immunity to some dengue serotype. The non-neutralizing antibodies produced 
by cross reaction during a primary infection or passively obtained from a mother 
to newborns are adhered to epitopes of dengue virus infections facilitating the 
entry of cells to Fc-receptors. This may contribute to a person’s viral load increase 
resulting in strong immune response that includes inflammatory mediators [19]. 
Cytosines may enable plasma extravasation. In secondary infections, memory 
T-cells caused by previous reactions to dengue activate, replicate, produce cyto-
sines and die of apoptosis. This can be correlated with disease severity [16]. The 
patient’s background is important when ruling out other causes of this disease, for 
instance, other flavivirus presence like YFV, Saint Louis encephalitis virus (SLEV), 
Zika virus (ZIKV), WNV. Alphavirus like Chikungunya (CHIKV), Mayaro virus 
(MAYV), Venezuelan Equine Encephalitis virus (VEE), Bunyavirus like Oropouche 
virus (OROV), group C virus, Guaroa virus (GROV), Influenza virus, arenavirus, 
filovirus as well as other microorganisms can cause the disease with symptoms with 
similar symptoms such as malaria, Leptospirosis, typhoid fever, rickettsia diseases, 
etc. [1]. Dengue infections with different serotypes as well as the sequence of these 
infected patients may influence on the severity of the disease. In a study carried out 
in Singapore, between 2005 and 2011, febrile adult patients found in DENV-1 cases 
that were associated with dengue hemorrhagic fever (adjusted RR = 1.74) and severe 
dengue (adjusted RR = 2.1) were assessed, while DENV-2 had a low risk of dengue 
hemorrhagic fever (adjusted RR = 0.5) [20]. A special attention should be given 
to the clinical features of this disease in order to learn differences that lead to the 
identification of microorganisms causing the disease. It was found that there were 
no elevated hematocrit or shock cases in CHIKV infection as compared to dengue 
cases with high hematocrit in 40–69% of cases and shock in 10–39% of cases when 
comparing the clinical data and laboratory features within dengue infections and 
chikungunya [21]. The arthralgias were more frequent in CHIKV in 70–100% of 
cases as compared to at least 10% of dengue cases. The Zika infections may present 
Oedema in limbs as compared to dengue and chikungunya which is low or nil. The 
presence of this type of differences does not exclude atypical complications and 
presentations of the disease, thus the laboratory diagnosis plays a crucial role [22].
DENV, ZIKV and CHIKV are transmitted by Aedes aegypti vector. Therefore, 
the areas where the disease is spread may be the same leading potentially to 
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co-infections. Co-infection cases within different dengue serotypes have been 
reported in various countries like Peru where isolation of DENV-1 and DENV-3 in 
the department of Madre de Dios was reported [23]. Although this type of find-
ings, the connection between dengue co-infections and severity of the infection 
needs to be further examined. Reports of DENV and CHIKV co-infections have 
been exhibited since 1964 in Asia, Africa, the Caribbean, North America, South 
America. Dengue and malaria co-infections have been reported in various countries 
such as India, Pakistan, Indonesia, Japan, Malaysia, Brazil and many others; and 
even co-infections among dengue, malaria and chikungunya have been reported 
in South Africa and Asia. A systematic review to determine global prevalence and 
distribution of malaria, dengue and chikungunya coinfections reported evidence 
of coinfections within these agents in 42 countries. The most prevalent confection 
was malaria/dengue followed by dengue/chikungunya, Malaria/Chikungunya and 
Malaria/Dengue/Chikungunya [24]. Clinical presentations between dengue and 
malaria are alike so it can sometimes cause a co-infection misdiagnosis. Anemia is a 
major symptom of infections caused by malaria which are not presented in dengue 
cases but it is often in this type of co-infections. On the other hand, lowering of 
platelets and hemoglobin content, reduced aspartate aminotransferase levels and 
elevated alanine aminotransferase levels are also observed [25].
In 1970, dengue disease was classified as non-classical dengue fever, classical 
dengue fever, dengue hemorrhagic fever and dengue shock syndrome. Sometime 
after this, various studies reported lack of correlation between classification and 
disease severity [26]. This classification showed a high specificity in the identifi-
cation of hemorrhagic dengue; however, its sensitivity was low when detecting 
severe dengue cases requiring medical care and/or hospitalization. Thus, the WHO 
proposed a new classification according to the level of clinical severity by dividing 
dengue disease in two categories, severe dengue and non-severe dengue in 2008 
[1]. This classification makes possible to establish the management and improve 
notifications for a better epidemiological surveillance so that warning signs and 
early warning of severe cases requiring hospitalization are proposed [1]. Regarding 
a study conducted to compare both classifications, it was found that the sensitivity 
of the new classification to detect severe cases was 65%, and the old classification 
was 30%. The new classification had 72% of sensitivity to detect patients needing 
advanced medical services and the old classification only had 32%. Further studies 
alike indicate that the WHO classification in 2009 has brought benefits in epide-
miology and clinical use, some others have proposed to include other variables on 
severe dengue categories in order to increase sensitivity in a case detection that may 
require advanced medical care [27].
5. Dengue vectors and mechanisms of infection
Dengue virus is mainly transmitted by Aedes aegypti and Aedes albopictus 
mosquitoes. Aedes aegypti is a tropical mosquito regarded as the most important 
disease transmission vector in urban areas, there are also other vector viruses like 
ZIKV and CHIKV. Dengue outbreaks have also been attributed to Aedes albopictus, 
Aedes polynesiensis and various species of complex Aedes scutellaris [1]. Aedes aegypti 
is a species with a strong predilection for human blood adapted to urban zones, 
especially in human dwellings; it is an efficient vector due to certain features like 
the egg-laying in a wide range of containers, the egg resistance to drying and the 
capacity of the female mosquito to bite in multiple occasions until they meet their 
need of blood. Aedes albopictus has adapted to temperate and tropical climates and 
it is a zoophilic and anthrophilic species and as well as Aedes aegypti, they both feed 
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during the day [1]. Some laboratory studies have reported that Aedes albopictus can 
become infected and transmit other 22 arboviruses such as CHIKV, Eastern equine 
encephalitis virus (EEEV), Ross river virus (RRV), Western equine Encephalitis 
(WEE), YFV among others [28]. The vertical virus transmission (transovarial or 
transovum) of an infected female mosquito to its eggs and subsequent progeny 
provides a mechanism as the arbovirus may be maintained in nature during climate 
conditions such as cold periods in temperate and hot regions, and dry in tropical 
areas or during the lack of susceptible vertebrate host. Many flaviviruses like YFV, 
Japanese encephalitis virus (JEV), SLEV, WNV can be transmitted in a verti-
cal manner in its natural vectors [29]. Such natural transmission for DENV has 
already been approved by Aedes aegypti and Aedes albopictus; however, it occurs in 
a smaller proportion in Aedes aegypti. Moreover, its potential for transmission and 
maintenance of disease in nature has not been established yet. The preference of 
Aedes aegypti for little organic matter in water or clean water when it comes to lay 
eggs provides information about the possible places that these mosquito larvae may 
be found. However, some studies reported that septic tanks have been identified 
as places where a high Aedes aegypti replication can occur [30]. A study in Brazil 
assessed rudimentary cesspits as possible Aedes aegypti breeding sites identifying 
immature and adult forms of Aedes aegypti in cesspits. The average number of 
insects found was similar to the one reported in common breeding habitats which 
confirmed the new place of breeding of this vector [30]. Thus, the identification 
of new Aedes aegypti breeding sites indicates a change in habits or an adaptation of 
the mosquito in its environment that also need to be considered in vector control 
strategies of Aedes aegypti. Climatic factors play a significant role in its biological 
cycle and displacement of dengue vector. In a study about the effect of temperature 
on mosquitoes, it was found that mosquitoes maintained at 20°C were less sensitive 
to the infection and died in less time which lessened the likelihood of midgut infec-
tion without affecting the extrinsic incubation period of DENV as compared to a 
constant 10°C temperature range [31].
6. Dengue virus jungle cycle and reverse zoonosis
DENV can circulate in jungle cycles where virus can remain in place using non-
human primates (NHP) as reservoirs or viruses transmitted in an urban cycle can 
infect non-human primates (‘spillback’ or ‘reverse zoonosis’) [12]. The urban and 
jungle cycles are shown to exist in Asia and Africa, in countries such as Malaysia, 
Senegal, the Philippines where DENV would be identified by a virus isolation 
from species such as Presbytis obscura, Erythrocebus patas, and Macaca fascicularis 
respectively [32]. Studies conducted in South East Asia reported antibodies in non-
human primates in Indonesia, the Philippines, Cambodia, Vietnam and Malaysia. 
DENV viral isolation or identification by RT-PCR in NHP has not been reported in 
Americas but wild caught patas monkeys (Erythrocebus patas) and rhesus macaques 
(Macaca mulatta) showing antibodies against DENV by PRNT were reported in a 
study carried out between 2010 and 2012 in Puerto Rico [32]. As no evidences of 
DENV jungle cycle in America were shown, it is believed that these results may 
represent a spillback infection and non-human primates would get the infection 
of urban cycles presented in the population. In Argentina 2020, antibodies against 
DENV-1 y DENV-3 in howler monkeys (Alouatta caraya) were found; and in Brazil 
between 2006 and 2014, low antibodies against DENV in free-living golden headed 
lion tamarins (Leontopithecus chrysomelas) were found [32]. These cases were also 
assumed to result from spillback infection. A study in Thailand in 2008–2009 
identified 6 DENV positive-dogs by RT-PCR and/or viral isolation in urban areas, 
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2 were DENV-2 positive and 4 were DENV-3 positive in a rubber plantation area 
[33]. It is necessary to continue with this type of studies in these animals in order to 
develop a viremia high enough to infect mosquitoes. More than 200 viruses from 27 
families, including flaviviridae, was isolated or detected in bats and several studies 
have shown DENV nucleic acids and/or antibodies present in Neotropical wildlife. 
A study in Costa Rica suggest that bats are infected accidentally by DENV because 
the RNA quantification in blood was low below the minimum infectious dose of 
mosquito that is needed to maintain the transmission cycle for the virus. Thus, they 
were considered as dead-end hosts for dengue virus [34].
7. Problems of dengue diagnosis
A series of multiple variant testing have been carried out for dengue diagnosis 
depending on a person’s infection phase, these tests are conducted with different 
immunological targets for virus recognition, a part of its structure or a reaction 
in an infected person or an animal’s body indicating an exposure to DENV [35] 
(Table 2).
In a dengue study, diagnostic tests display numerous problems which we will 
describe briefly. The presence of false positive as a result of contamination and dif-
ferent variants of RT-PCR such as endpoint PCR, nested PCR, real-time PCR as well 
as the use of different primers and enzymes lead to variations in levels of sensitivity 
and specificity. Some commercial test enables the identification of different micro-
organisms by utilizing RT-PCR, PCR tests and the detection of the product in about 
an hour. The RUO Film Array Global Fever Panel tests are utilized for the detection 
of 6 bacterias, 4 protozoans and 9 viruses like Chikungunya virus, Crimean-Congo 
hemorrhagic fever virus, Ebola virus, Lassa virus, Marburg virus, West Nile virus, 
Yellow fever virus, Zika virus and Dengue virus. Whole blood (EDTA) is used as a 
sample. The use of automation equipment can help to reduce contamination prob-
lems and deliver results in a short time as well as providing diagnosis for 19 patho-
gens. Regarding to improvements for this type of systems the equipment can only 
process one sample at a time, and the study is expensive. The rapid tests do not need 
sophisticated equipment or qualified staff, it is feasible in situ and they are inexpen-
sive. Nonetheless, its sensitivity and specificity are not as higher as other tech-
niques. Cell cultures are often used for dengue virus isolation. Many cell lines are 
used for virus isolation; however, their sensitivity can vary depending on the type 
of cell line, the clone, the system used for viral isolation and the sample type used 
for isolation [35, 36]. In order to isolate DENV, it is preferable to use C6/36 cell line 
obtained from Aedes albopictus mosquito salivary glands that is replicated at 28°C as 
Diagnostic test Immunological target
Polymerase chain reaction (PCR) RNA detection
Rapid tests NS1, IgM, IgG
Virus isolation Virus
Immunofluorescence (IF) Virus, IgM, IgG
Plaque assay (PA) and fluorescent focus assay (FFA) Virus (titer)
Enzyme-linked immunosorbent assay (ELISAS) NS1, IgM, IgG, IgA
Neutralization tests Neutralizing antibodies (IgG)
Table 2. 
Most commonly used diagnostic tests for diagnosing dengue.
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it has higher sensitivity than Vero or BHK-21 (mammalian lines). Some researchers 
suggest using a variety of C6/36 HT which grows at 33°C. Such cell is considered to 
be more sensitive than the traditional C6/36, and it is recommended to use the shell 
vial or shell vial modified method instead of the traditional or standard isolated 
system in order to achieve better results. In the modified shell vial method, the cell 
culture is infected, centrifuged and incubated for 10–15 days, then positive cultures 
by indirect immunofluorescence are identified [35, 36]. Many laboratories do two 
or three passages from cell cultures following an assessment of virus presence 
conducted by IFI. This increases more the number of isolations but the cost of the 
testing goes up and the time needed to obtain the results raises. The quantifica-
tion or viral load may be run by real time PCR utilizing a standard reference that 
in comparison with the sample allow us to assess the number of genetic material 
copies from the sample [35, 36]. When it is intended to quantify infecting viruses 
in biological samples for producing antigens or vaccines, is preferred to use PA in 
Vero or BHK-21 cells [35, 36]. One alternative for viral titration, depending on the 
study performed and especially when evaluating viral load in mosquitoes, is the use 
of FFA that is a mixture of plaque assay and immunofluorescence test and it allows 
the use of C6/36 cells containing higher sensitivity than the above-mentioned cells 
[35, 36]. IF and ELISAS tests are relatively low cost and they may occur commer-
cially or may be designed. Many of their components as antibodies and antigens 
can be produced in the laboratory at lower costs but it is necessary a good quality 
control of production so that there can be variations in job titles of lots that may 
affect test results [35, 36]. Neutralization tests can be performed under different 
techniques such as PRNT, microneutralization, microneutralization-ELISA. These 
tests facilitate the high specificity type IgG neutralizing antibodies detection. 
However, the levels of sensitivity in relation to the cell line, the strain of virus and 
the technique used are due to cell cultures. Other problems have yet been overcome 
are DENV cross-reactions with other flavivirus and within the same serotypes 
in serological tests like ELISAS, IFI and even considered to be gold standard like 
neutralization test by plaque reduction (PRNT) exhibiting cross-reactions. Cross-
reactivity between serotypes is frequent and it occurs particularly in epitope on NS 
protein for the conservation or in conserved epitopes on E glycoprotein and may 
vary according to homology between every DENV serotype and genotype. The use 
of specific monoclonal antibodies for every dengue serotype in the IFI tests improve 
greatly the specificity of the test as compared to the use of HMAF. The use of tests 
allows to detect multiple pathogens at the same time like CDC DENV-1-4 rRT-PCR 
multiplex detecting infecting dengue virus serotype and it was approved by FDA in 
2013 [35, 37]. The CDC Trioplex rRT-PCR assay uses real-time (TaqMan®) RT-PCR 
assays for detection and differentiation of RNA from DENV, CHIKV and ZIKV in 
serum samples, whole blood (EDTA), cerebrospinal fluid. This also enables the 
RNA detection of ZIKV in urine and amniotic fluids. FDA has authorized the use of 
this test under an Emergency Use Authorization (EUA) [38].
8. Animal models for dengue
It is not yet found a suitable animal model expressing all characteristics for 
dengue disease [39]. Among the most common models used for research are 
mice showing drawbacks with low-level virus replication of clinical samples, and 
non-human primates showing a problem for not expressing the clinical disease 
in the same manner as humans [39]. The use of nursing mice used in intracranial 
inoculations with high viral load inducing neurological diseases and paralysis are 
still been used; however, its use continues more for the production of biological 
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supplies. DENV can slightly replicate in mice A/J, BALB/c and C57BL/6. Mice A/J 
and BALB/c can die of paralysis [39, 40]. For animal studies, it is considered that an 
infection with DENV 104–106 PFU (plaque-forming units) concentrations imitate 
inoculum concentrations of a mosquito bite [39]. The mouse model is generally 
used initially to assess vaccines being the most suitable the immunocompetent mice 
but when it exhibits low viremia may result in the underestimation of the results. 
The use of nursing mice is a good way to assess possible candidate vaccines induc-
ing neurovirulence. Although the NHP do not develop the disease, the antibody 
seroconversion produced is human-like [39, 40].
9. Antivirals for treating dengue
At the moment, there is no antiviral therapy for DENV treatment. It is believed 
that the compounds working as inhibitors of RNA-dependent RNA polymerase have 
shown low efficiency. Moreover, there is a possibility that viral epitopes of DENV 
may trigger an immune cell response, preceded by development of severe disease. 
Thus, these epitopes are examined as targets for antiviral productions and they are 
known as DENV entry inhibitors and can be used in combination with inhibitors of 
the virus replication in order to increase efficiency.
Inhibition of DENV attachment and entry into the host cell can inhibit immune 
activation.
Various compounds as peptide entry inhibitors, DN59 and 1OAN1 may inhibit 
the antibody-dependent enhancement (ADE) in vitro. The doxorubicin antibiotic 
SA-17 is structured similarly to tetracycline and it has an antiviral activity against 
DENV serotype 1, 2 and 3 in Vero and C6/36 cells interfering with viral entry by 
binding to the hydrophobic pocket of the E-protein without exhibiting virucidal 
activity. The glycosidase inhibitors are unpopular due to its toxicity and low speci-
ficity but may help understand E-protein glycosylation processes. The binding 
agents to carbohydrates occur only during the stage of virus adsorption to the host 
cell. Concanavalin and agglutinins of wheat germ can bind N-acetylglucosamine 
residues and the percentage of DENV-lytic plaques in BHK cells can be reduced. 
Plant lectins such as Hippeastrum hybrid, Galanthus nivalis, and Urtica dioica inhibit 
DENV-2 infection in Raji/DC-SIGN cells. The compounds of heparan sulfate are 
potential recipients for DENV. Dengue E protein domain III is responsible for the 
interaction of heparan sulfate, and it is believed to be in all DENV serotypes and to 
have epitopes that are recognized by neutralizing antibodies. The suramin is similar 
to heparan sulfate and persulfated glycosaminoglycan, they bind to a polyanion-
binding site of DENV E protein by inhibiting infection. The sulfated polysaccha-
rides extracted from red algae, carrageenans and DL-galactan presented antiviral 
activity against 4 serotypes of dengue; however, the antiviral activity of DENV-4 
DENV-1 weakened in Vero cells and in human Hepatocytes [41, 42].
10. Dengue vaccine
In May 2019, the U.S. Food and Drug Administration (FDA) approved the use 
of Dengvaxia®, a vaccine against DENV that may be used in people aged from 9 to 
45 years old [43]. This vaccine utilizes a live attenuated chimeric yellow fever/den-
gue virus based on a Yellow fever 17D vaccine virus backbone chimerized with prM 
and E proteins from DENV1–4 replacing the YF prM and E, and 3 doses are admin-
istered every 6 months. In phase III trials the overall protective efficacy was 56.7% 
and 60.8% in South East Asia and Latin America countries, respectively. In 2017, the 
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vaccine manufacturer, Sanofi Pasteur, announced that some people getting the vac-
cine without having been previously infected by DENV may be at risk for develop-
ing severe dengue if the disease is acquired after immunization [43]. The vaccine 
candidates utilize strategies such as vaccines of Live-attenuated virus, Inactivated 
virus, Recombinant protein, DNA vaccine, Viral vector vaccine, Virus like particles 
and others. Two vaccine candidates (DENVax and TV003/TV005) are being tested 
in efficacy trials in both Asia and Latin America. DENVax is a tetravalent recom-
binant live-attenuated dengue vaccine licensed to Takeda. The live virus vaccine 
utilizes chimerization with DENV-2 PDK-53 as the backbone with DENV-2/-1, 
-2/-3, and -2/-4 chimeras are created by replacing the DENV-2 prM and E genes 
with the respective genes from the other DENV serotypes. Other vaccine candidate 
is TV003/TV00 with a whole attenuated virus for three of four serotypes (attenu-
ated by deletion of 30 nucleotides from 3′ UTR of DENV-1, DENV-3, DENV-4, and 
a chimeric DENV-2/DENV-4) [44]. In spite of having already a vaccine available to 
prevent dengue, there is a need to further research in order to improve the vaccine 
for dengue or to produce a new vaccine which enables improvements in certain 
aspects, for example, a single dose that may immunize for extended periods of time 
even lifelong, the vaccine effectiveness no longer relying on previous exposure 
to flavivirus or DENV, the age of group to provide protection being the broadest 
possible including children under 9 years old, and its administration decreasing the 
chances of getting the most aggressive dengue disease at no point post vaccination.
11. Conclusions
Dengue is still a major public health concern worldwide. Several natural and 
social factors have contributed to the number of cases increased in recent decades. 
The efforts attained in the search of new antivirals and vaccines, and prevention 
and control strategies for this disease have not proved sufficient. However, the sci-
ence and knowledge development acquired up to now provide us the tools we need 
to, and mark the way to follow, in order to achieve a control of this disease.
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